BioRestorative Therapies, Inc. - רווח למניה בשנים עשר החודשים האחרונים BRTX

BioRestorative Therapies expenses rely on external R&D investment and the risks of regulatory rejections. The year-over-year change in EPS (TTM) visualizes these financial fluctuations, where the value of 25.20 serves as the current metric. Business stability is based on its own spinal treatment laboratory, while process continuity is ensured by a network of US research centers.
BioRestorative - פילוחים אנליטיים ומדדי מפתח (BRTX)

The long-term reliability of BioRestorative Therapies (BRTX) depends on its ability to commercialize cell therapy to combat metabolic disorders and back pain. By analyzing the year-over-year EPS dynamics over the last 12 months, an investor assesses the percentage change in net income per share, which allows for the determination of business scaling rates and confirms the stability of its financial foundation.